This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Stocks to Watch as Dental Supplies Recovers Amid Tariff Headwind
by Indrajit Bandyopadhyay
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are CAH, MMSI, XRAY and CNMD.
Merit Medical (MMSI) Surges 8.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Merit Medical (MMSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ALGN or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALGN vs. MMSI: Which Stock Is the Better Value Option?
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now
by Zacks Equity Research
Merit Medical's strong product portfolio raises optimism about the stock.
GE HealthCare's Latest Product Launch to Boost Cardiology Care
by Zacks Equity Research
GEHC's latest commercial launch of Flyrcado and the grant of pass-through status by CMS aim to serve a wider patient pool across the United States.
Merit Medical Stock May Rise as WRAPSODY CIE Shows Strong Results
by Zacks Equity Research
MMSI unveils 12-month efficacy data for WRAPSODY CIE, highlighting its advanced technology in vascular access maintenance and potential to improve patient outcomes.
Stereotaxis Jumps 15% on NVIDIA's AI-Driven Collaboration: Is It a Buy Now?
by Urmimala Biswas
The collaboration, highlighted at NVIDIA's GTC conference, aims to integrate artificial intelligence into surgical robotics, potentially enhancing Stereotaxis' technological capabilities.
MMSI Announces Commencement of Patient Enrollment in PREEMIE Study
by Zacks Equity Research
Merit Medical aims to improve care for vulnerable premature infants by evaluating the safety and efficacy of the Bloom Micro Occluder System for treating PDA in the specified patient pool.
MMSI Stock Gains in Pre-Market Post Q4 Earnings Beat, Margins Up
by Zacks Equity Research
Merit Medical benefits from revenue growth in both segments and all its product categories within its Cardiovascular unit in the fourth quarter of 2024.
Compared to Estimates, Merit Medical (MMSI) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Merit Medical (MMSI) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 12.05% and 0.93%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Fresenius Medical, Masimo, Merit Medical Systems and Inogen
by Zacks Equity Research
Fresenius Medical, Masimo, Merit Medical Systems and Inogen are included in this Analyst Blog.
What to Expect From These 4 Medical Device Stocks in Q4 Earnings?
by Indrajit Bandyopadhyay
Here is a sneak peek into how four Medical Device stocks, namely FMS, MASI, MMSI and INGN, are expected to fare in their quarterly results, slated to be released tomorrow.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Gear Up for Merit Medical (MMSI) Q4 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Merit Medical (MMSI) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Here is Why Growth Investors Should Buy Merit Medical (MMSI) Now
by Zacks Equity Research
Merit Medical (MMSI) could produce exceptional returns because of its solid growth attributes.
GE HealthCare Q4 Earnings Beat Estimates, Sales Miss, Net Margin Rises
by Zacks Equity Research
GEHC's fourth-quarter results reflect strength in the Advanced Visualization Solutions and Pharmaceutical Diagnostics segments. The bottom line improves on better pricing.
West Pharmaceutical Services (WST) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 4% and 1.25%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Ecolab Set to Report Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Robust segmental performances are likely to have driven ECL's performance in the fourth quarter.
Will Lower Commercial Premiums Hurt Humana's Q4 Earnings?
by Zacks Equity Research
HUM's Q4 results are likely to suffer a blow due to escalating operating costs, partly offset by membership growth in the Individual and Group Medicare Advantage business lines.
Here's Why Merit Medical (MMSI) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
MCK Stock Down on Q3 Earnings & Sales Miss, Gross Margin Contracts
by Zacks Equity Research
McKesson's third-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
Looking for a Growth Stock? 3 Reasons Why Merit Medical (MMSI) is a Solid Choice
by Zacks Equity Research
Merit Medical (MMSI) possesses solid growth attributes, which could help it handily outperform the market.
Can Sustained Product Demand Drive BDX Stock Before Q1 Earnings?
by Zacks Equity Research
The continued solid uptake of BD's products is expected to have driven fiscal first-quarter revenues despite transitory market dynamics.
Here's Why Merit Medical (MMSI) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.